MA29397B1 - Methode de traitement ou de prevention du diabete de type 2 - Google Patents

Methode de traitement ou de prevention du diabete de type 2

Info

Publication number
MA29397B1
MA29397B1 MA30305A MA30305A MA29397B1 MA 29397 B1 MA29397 B1 MA 29397B1 MA 30305 A MA30305 A MA 30305A MA 30305 A MA30305 A MA 30305A MA 29397 B1 MA29397 B1 MA 29397B1
Authority
MA
Morocco
Prior art keywords
treating
diabetes type
preventing diabetes
diabetes
administering
Prior art date
Application number
MA30305A
Other languages
English (en)
Inventor
Seo Woun
Original Assignee
Besins Int Lab
Unimed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Int Lab, Unimed Pharmaceuticals Inc filed Critical Besins Int Lab
Publication of MA29397B1 publication Critical patent/MA29397B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE GÉNÉRALEMENT UNE MÉTHODE DE TRAITEMENT OU DE PRÉVENTION DU DIABÈTE DE TYPE 2, OU DE RÉDUCTION DU RISQUE DE DÉVELOPPER LE DIABÈTE DE TYPE 2. ELLE CONCERNE PLUS PARTICULIÈREMENT UNE MÉTHODE D'ADMINISTRATION D'UNE COMPOSITION DE GEL TRANSDERMIQUE AQUEUX À BASE D'ALCOOL POUR TRAITER OU PRÉVENIR LE DIABÈTE DE TYPE 2; ET UNE MÉTHODE D'ADMINISTRATION D'UNE COMPOSITION DE GEL TRANSDERMIQUE AQUEUX À BASE D'ALCOOL POUR AUGMENTER LA RÉGULATION GLYCÉMIQUE CHEZ UN MALADE.
MA30305A 2005-04-08 2007-10-17 Methode de traitement ou de prevention du diabete de type 2 MA29397B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66960605P 2005-04-08 2005-04-08

Publications (1)

Publication Number Publication Date
MA29397B1 true MA29397B1 (fr) 2008-04-01

Family

ID=36609553

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30305A MA29397B1 (fr) 2005-04-08 2007-10-17 Methode de traitement ou de prevention du diabete de type 2

Country Status (23)

Country Link
US (1) US20070088012A1 (fr)
EP (1) EP1865990B1 (fr)
JP (1) JP2008534644A (fr)
CN (1) CN101155598A (fr)
AT (1) ATE486612T1 (fr)
AU (1) AU2006233812B2 (fr)
BR (1) BRPI0610454B8 (fr)
CA (1) CA2604077A1 (fr)
DE (1) DE602006017982D1 (fr)
DK (1) DK1865990T3 (fr)
EA (1) EA013568B1 (fr)
ES (1) ES2354829T3 (fr)
HR (1) HRP20110038T1 (fr)
IL (1) IL186356A (fr)
MA (1) MA29397B1 (fr)
MX (1) MX2007012347A (fr)
NO (1) NO340565B1 (fr)
PL (1) PL1865990T3 (fr)
PT (1) PT1865990E (fr)
SI (1) SI1865990T1 (fr)
TN (1) TNSN07372A1 (fr)
UA (1) UA90307C2 (fr)
WO (1) WO2006108719A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
PT2450041T (pt) * 2005-10-12 2018-11-16 Unimed Pharmaceuticals Llc Gel de testosterona melhorado e método para a sua utilização
WO2009055859A1 (fr) 2007-11-02 2009-05-07 Acrux Dds Pty Ltd Système d'administration transdermique pour hormones et stéroïdes
US20110190192A1 (en) * 2009-12-15 2011-08-04 Cebix Inc. Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
US20230285283A1 (en) * 2020-07-29 2023-09-14 Kydes Pharmaceuticals, Llc Pharmaceutical formulations comprising tadalafil
CN114632092B (zh) * 2022-05-17 2022-08-23 北京第一生物化学药业有限公司 睾丸片在制备具有降糖活性的药物中的应用

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2155658A (en) * 1936-01-08 1939-04-25 Chemische Forschungs Gmbh Surgical and medical preparations
US3121042A (en) * 1959-05-04 1964-02-11 Ercoli Alberto Oral compositions containing 3-enolethers of methyltestosterone
US3164520A (en) * 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
US4009254A (en) * 1974-05-06 1977-02-22 Colgate-Palmolive Company Topical compositions
US3939111A (en) * 1974-07-01 1976-02-17 The B. F. Goodrich Company Stable polyurethane solutions
US4197316A (en) * 1975-07-23 1980-04-08 Scott Eugene J Van Treatment of dry skin
NL7510104A (nl) * 1975-08-27 1977-03-01 Akzo Nv Werkwijze ter bereiding van een oraal werkzaam farmaceutisch preparaat.
US4078060A (en) * 1976-05-10 1978-03-07 Richardson-Merrell Inc. Method of inducing an estrogenic response
DE2747531A1 (de) * 1977-10-22 1979-04-26 Basf Ag Substituierte 3-aminopyrazole
US4442094A (en) * 1980-12-23 1984-04-10 Merck & Co., Inc. (3-Aralkylamino-2-or-propoxy)heterocyclic compounds
US4440777A (en) * 1981-07-07 1984-04-03 Merck & Co., Inc. Use of eucalyptol for enhancing skin permeation of bio-affecting agents
US4447562A (en) * 1981-07-15 1984-05-08 Ivani Edward J Amino-polysaccharides and copolymers thereof for contact lenses and ophthalmic compositions
US4496556A (en) * 1982-08-16 1985-01-29 Norman Orentreich Topical applications for preventing dry skin
DE3315654A1 (de) * 1983-04-29 1984-10-31 Bosch Gmbh Robert Polarographischer messfuehler fuer die bestimmung des sauerstoff-gehaltes in gasen
NL8301550A (nl) * 1983-05-03 1984-12-03 Gist Brocades Nv Imidazolethanol esters.
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
US4725439A (en) * 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4663157A (en) * 1985-02-28 1987-05-05 The Proctor & Gamble Company Sunscreen compositions
US5731303A (en) * 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
US4820724A (en) * 1986-03-31 1989-04-11 University Of Southern California Dual phase solvent carrier system
US4981696A (en) * 1986-12-22 1991-01-01 E. I. Du Pont De Nemours And Company Polylactide compositions
US4906169A (en) * 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US5013553A (en) * 1987-06-30 1991-05-07 Vipont Pharmaceutical, Inc. Drug delivery devices
US4920203A (en) * 1987-12-17 1990-04-24 Allied-Signal Inc. Medical devices fabricated from homopolymers and copolymers having recurring carbonate units
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
EP0595796B1 (fr) * 1989-07-07 2003-01-15 Endorecherche Inc. Procede de traitement des maladies associees aux androgenes
US5116828A (en) * 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
JPH04261119A (ja) * 1991-02-13 1992-09-17 Lintec Corp 経皮吸収型貼付剤
US5208013A (en) * 1991-06-03 1993-05-04 Olympus International, Inc. Composition for skin care and protection
US5487898A (en) * 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
JP3202777B2 (ja) * 1992-01-24 2001-08-27 リンテック株式会社 経皮吸収促進剤及びテープ製剤
US5629019A (en) * 1992-02-27 1997-05-13 Alza Corporation Formulations with hydrophobic permeation enhancers
TW224048B (fr) * 1992-03-30 1994-05-21 Hoechst Roussel Pharma
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
WO1994013257A1 (fr) * 1992-12-16 1994-06-23 Creative Products Resource Associates, Ltd. Lotion occlusive ou semi-occlusive pour le traitement de maladies ou de desordres cutanes
US5881926A (en) * 1993-03-11 1999-03-16 Taro Pharmaceutical Industries, Ltd. Pharmaceutical compositions in semisolid form and a device for administration thereof
US6010691A (en) * 1993-03-19 2000-01-04 The Regents Of The University Of California Methods for enhancing permeation of a topically administered physiologically active substance
EP0696919B1 (fr) * 1993-04-05 2002-01-30 Competitive Technologies, Inc. Diagnostic et traitement des dysfonctionnements erectiles
PT698393E (pt) * 1993-05-19 2002-10-31 Hisamitsu Pharmaceutical Co Agente de solubilizacao e preparacao para uso externo contendo o mesmo
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US6024974A (en) * 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
US5629021A (en) * 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
AT408067B (de) * 1995-03-17 2001-08-27 Gebro Pharma Gmbh Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung
FR2732223B1 (fr) * 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US5882676A (en) * 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
US5902603A (en) * 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
US6036977A (en) * 1995-09-29 2000-03-14 L.A.M. Pharmaceutical Corp. Drug preparations for treating sexual dysfunction
DE19619045C1 (de) * 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
IT1283102B1 (it) * 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
US5730987A (en) * 1996-06-10 1998-03-24 Omar; Lotfy Ismail Medication for impotence containing lyophilized roe and a powdered extract of Ginkgo biloba
US5708038A (en) * 1996-06-13 1998-01-13 Univera Pharmaceuticals, Inc. Method of using aloe vera as a biological vehicle
US5863560A (en) * 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US6019988A (en) * 1996-11-18 2000-02-01 Bristol-Myers Squibb Company Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US6019997A (en) * 1997-01-09 2000-02-01 Minnesota Mining And Manufacturing Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents
GB9700878D0 (en) * 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US6342250B1 (en) * 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
JP2004515446A (ja) * 1997-11-24 2004-05-27 ユニバーシティ・オブ・フロリダ・リサーチ・ファンデーション・インコーポレーテッド テストステロン阻害剤及びニューロンの保護のためのその用途
EP2002839A1 (fr) * 1998-04-17 2008-12-17 Ortho McNeil Pharmaceutical, Inc. Compositions pharmaceutiques contenant un acide folique, et procédés associés et systèmes de livraison
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
US5880117A (en) * 1998-07-13 1999-03-09 Arnold; Patrick Use of 4-androstenediol to increase testosterone levels in humans
US6207694B1 (en) * 1998-07-27 2001-03-27 Howard Murad Pharmaceutical compositions and methods for managing scalp conditions
US6117446A (en) * 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
US6187750B1 (en) * 1999-08-25 2001-02-13 Everyoung Technologies, Inc. Method of hormone treatment for patients with symptoms consistent with multiple sclerosis
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
WO2001052823A2 (fr) * 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions et methodes permettant d'elaborer un profil de liberation dans l'administration transdermique d'agents actifs
HUP0301773A3 (en) * 2000-04-07 2006-02-28 Tap Pharmaceutical Prod Inc Apomorphine derivatives and methods for their use
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
EP1315502B1 (fr) * 2000-08-30 2010-03-17 Unimed Pharmaceuticals, LLC Methode pour traiter la dyserection et augmenter la libido chez l'homme
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
JP5039252B2 (ja) * 2000-08-31 2012-10-03 ユニメッド ファーマシューティカルズ，リミティド ライアビリティ カンパニー 性機能低下を治療するための医薬組成物及び方法
FR2814074B1 (fr) * 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique
EP1347764B1 (fr) * 2000-12-22 2007-03-14 Dr. August Wolff GmbH & Co. KG Arzneimittel Gel a base d'alcool pour traiter l'hypogonadisme par voie trans-scrotale
CA2446622C (fr) * 2001-05-11 2012-08-14 Elan Corporation, Plc Sels d'acide isostearique utilises comme accelerateurs de permeation
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
US20040072810A1 (en) * 2001-11-07 2004-04-15 Besins International Belgique Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
WO2003066130A2 (fr) * 2002-02-07 2003-08-14 Massachusetts Institute Of Technology Systemes d'administration transdermique d'un medicament
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US6931903B2 (en) * 2002-06-28 2005-08-23 Gary A. Knudson Apparatus and method for roll forming shaped members
FR2851470B1 (fr) * 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
US20050025833A1 (en) * 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
RU2275930C2 (ru) * 2004-04-26 2006-05-10 ООО "РусГен" Композиция для коррекции возрастных изменений эндокринной системы человека (варианты) и способ получения фармацевтической формы на основе такой композиции
US20070082039A1 (en) * 2004-10-18 2007-04-12 Jones Gerald S Jr Synthesis of fatty alcohol esters of alpha-hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers, and topical gels for the transdermal delivery of steroids
AU2006235453A1 (en) * 2005-04-12 2006-10-19 Laboratories Besins International Method of treating or preventing bone deterioration or osteoporosis
US20070065494A1 (en) * 2005-08-03 2007-03-22 Watson Laboratories, Inc. Formulations and Methods for Enhancing the Transdermal Penetration of a Drug

Also Published As

Publication number Publication date
MX2007012347A (es) 2007-12-05
PT1865990E (pt) 2011-02-07
BRPI0610454B8 (pt) 2021-05-25
BRPI0610454B1 (pt) 2021-05-11
CN101155598A (zh) 2008-04-02
IL186356A0 (en) 2008-01-20
IL186356A (en) 2011-05-31
TNSN07372A1 (en) 2009-03-17
PL1865990T3 (pl) 2011-04-29
AU2006233812A1 (en) 2006-10-19
DE602006017982D1 (fr) 2010-12-16
US20070088012A1 (en) 2007-04-19
NO20075695L (no) 2008-01-07
WO2006108719A1 (fr) 2006-10-19
UA90307C2 (uk) 2010-04-26
AU2006233812B2 (en) 2011-07-28
JP2008534644A (ja) 2008-08-28
ES2354829T3 (es) 2011-03-18
NO340565B1 (no) 2017-05-15
DK1865990T3 (da) 2011-02-14
EP1865990B1 (fr) 2010-11-03
EA200702189A1 (ru) 2008-04-28
EP1865990A1 (fr) 2007-12-19
CA2604077A1 (fr) 2006-10-19
HRP20110038T1 (hr) 2011-02-28
EA013568B1 (ru) 2010-06-30
ATE486612T1 (de) 2010-11-15
BRPI0610454A2 (pt) 2010-06-22
SI1865990T1 (sl) 2011-02-28

Similar Documents

Publication Publication Date Title
MA29397B1 (fr) Methode de traitement ou de prevention du diabete de type 2
ATE374766T1 (de) 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
BRPI0810118A8 (pt) Método para tratar doença, método para efetuar profilaxia contra caa, uso de um agente, método para reduzir amilóide vascular em um paciente, e, kit para tratamento
EP3773880C0 (fr) Modulation thérapeutique pour traiter les anomalies de glycémie, y compris le diabète de type 2, et/ou pour réduire les niveaux d'hba1c
DE602006007093D1 (de) Kombinationstherapie zur Behandlung von Diabetes und dadurch bedingten Leiden sowie zur Behandlung von mittels Erhöhung des GLP-1-Spiegels im Blut verbesserten Leiden
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
NO20082790L (no) Behandling av type 2 diabetes med en kombinasjon av DPIV inhibitor og metformin eller thiazolidindion
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
NO20064124L (no) Anvendelse av metformin og orlistat for behandling eller forebygging av fedme
UA102669C2 (xx) Застосування інгібіторів dpp iv$применение ингибиторов dpp iv
MA30557B1 (fr) Composés de pyrrolopyrimidine et leurs utilisations.
PT1143955E (pt) Combinacao de inibidores de fbpase e sensibilizadores de insulina para o tratamento de diabete
EA200900940A1 (ru) Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
TW200724157A (en) A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
EA200971053A1 (ru) Способы лечения кожных язв
BR0212907A (pt) Métodos para tratamento ou prevenção de inflamação vascular usando inibidor(es) da absorção de esteróis
ATE525084T1 (de) Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus
BR0315314A (pt) Método para o tratamento ou prevenção de sintomas de vasomotores em um paciente com necessidade do mesmo
NO20070996L (no) Fremgangsmate for behandling av CCR2 medierte sykdommer eller lidelser
MA30485B1 (fr) Aminothiazoles et leurs utilisations
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BRPI0408004A (pt) composições e métodos para diagnóstico e tratamento de asma ou outras doenças alérgicas ou inflamatórias
NO20073104L (no) Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelser
WO2005053728A3 (fr) Protéines associées à l'adiposité et leur utilisation à des fins thérapeutiques et diagnostiques